Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...136137138139140141142143144145146...858859»
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Trial completion:  Effect of Evolocumab on Coronary Atherosclerosis (clinicaltrials.gov) -  Aug 30, 2023   
    P3,  N=55, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Xolair (omalizumab) / Roche, Novartis, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Linear IgA Bullous Dermatosis in a 7-year old Filipino Female (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_4248;    
    However in our case report, given that the patient has a low GG6PD result, Dapsone could not be given. A literature search for articles published in the last 5 years has shown that other modalities, including rituximab, omalizumab, etanercept, IVIg, topical corticosteroids, among others have been used successfully in adult and pediatric patients with varying severity of disease.
  • ||||||||||  Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
    Roflumilast in aphthosis spectrum. Spanish multicentre case series. (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_4140;    
    A literature search for articles published in the last 5 years has shown that other modalities, including rituximab, omalizumab, etanercept, IVIg, topical corticosteroids, among others have been used successfully in adult and pediatric patients with varying severity of disease. When aphthosis is associated with Beh
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Enbrel (etanercept) / Pfizer, Amgen
    Biologics for treatment of keloids and hypertrophic scars: a literature review (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2778;    
    In the RCT, etanercept improved 5/12 parameters with greater efficacy in pruritus reduction compared to triamcinolone acetonide (TAC) injections, while TAC improved 11/12 parameters with better cosmetic results. Although the current gold standard for keloid treatment is TAC injections, biologics may provide a treatment option for symptomatic relief and size reduction in patients with severe keloids and hypertrophic scars refractory to other therapies.
  • ||||||||||  Characteristics in patients with psoriasis treated with different biologics  (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2771;    
    Although the current gold standard for keloid treatment is TAC injections, biologics may provide a treatment option for symptomatic relief and size reduction in patients with severe keloids and hypertrophic scars refractory to other therapies. We investigated adult patients initiating adalimumab, etanercept, infliximab, secukinumab and ustekinumab for psoriasis, and divided them into treatment lines (first to third-line)...Some characteristics were neither equally distributed at baseline nor after one year of treatment: (i) biologic-na
  • ||||||||||  Quality of life in cancer patients undergoing targeted therapies (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2769;    
    While the selected treatments were generally well-tolerated and resulted in manageable adverse effects, the reported quality of life varied among patients. These findings underscore the importance of considering individual patient factors and tailoring treatment strategies to optimize both clinical outcomes and quality of life in this patient population.
  • ||||||||||  Cosentyx (secukinumab) / Novartis
    Paradoxical psoriasis due to secukinumab (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2737;    
    Deucravacitinib may be a valuable new treatment for patients with moderate to severe psoriasis. The most commonly associated agents are infliximab (>50% of cases), followed by adalimumab (30%) and etanercept (11%)2,3...Materials & Clinical case A 42-year-old woman, a history of smoking and severe hidradenitis suppurativa, Hurley III, DLQI 30, who underwent multiple surgical excisional and non-surgical treatments with topical and systemic drugs (antibiotics, isotretinoin)...Taking into account that the new biological drugs are expanding their indications, and therefore the number of patients treated with them, is necessary to recognize the cutaneous adverse events, which often require the intervention of the dermatologist to decide whether to continue treatment.5 Due to the above, research studies and report the paradoxical reactions of the new biological therapies are necessary, as well as, close surveillance of patients treated with them.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Atopic dermatitis and psoriasis vulgaris as concurrent conditions- a case report (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2669;    
    The history of atopic dermatitis must be an indication for an appropriate therapy and cyclosporine can be choose as a treatment for remission induction for both diseases. Whilst the majority of patients diagnosed with psoriasis vulgaris have a well-defined course, cases of psoriasis vulgaris overlapping with atopic dermatitis have been reported.
  • ||||||||||  rocatinlimab (KHK4083) / Kyowa Kirin, Amgen
    Rocatinlimab improves lichenification compared with placebo in adults with moderate-to-severe atopic dermatitis in a Phase 2b trial (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2552;    
    P2
    Roca improved EASI lichenification scores consistently in the H&N region and across all body regions vs. placebo at Week 16; responses with roca continued through Week 36 and were maintained up to Week 56. Together with previous data demonstrating that EASI score improvements from baseline were maintained up to Week 56 (despite being off treatment for 20 weeks), these data suggest that roca may have potential for disease modification across all body regions in adults with msAD.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Management and Outcomes of Toxic Epidermal Necrolysis Treated in Burns Centres: A Systematic Review (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2332;    
    This systematic review demonstrates the variation in management and mortality outcomes across management of TEN in burns centres with prospects for emerging immunomodulatory therapy. Our findings emphasise the importance of standardised protocols and evidenced-based interventions to optimise the management and improve prognosis of TEN patients within the burns centre setting.
  • ||||||||||  Vectibix (panitumumab) / Amgen, Takeda
    Panitumumab-associated stomatitis in a metastatic colorectal cancer patient: a case report (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2312;    
    Our findings emphasise the importance of standardised protocols and evidenced-based interventions to optimise the management and improve prognosis of TEN patients within the burns centre setting. Materials & A 63-year-old female, treated for metastatic colorectal cancer with 5-fluorouracil-folinic acid (5FU-FA) plus panitumumab (400mg), developed multiple painful oral
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Oncolytic virus:  A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. (Pubmed Central) -  Aug 29, 2023   
    P1
    This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities. Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity.
  • ||||||||||  olpasiran (AMG 890) / Amgen
    Journal:  Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population. (Pubmed Central) -  Aug 29, 2023   
    The ongoing Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction [OCEAN(a)]-Outcomes trial is evaluating whether Lp(a) lowering can reduce the incidence of cardiovascular events among patients with prior myocardial infarction (MI) or percutaneous coronary intervention (PCI) and elevated Lp(a) (?200 nmol/L)...Following adjustment for measured confounders, elevated Lp(a) remained independently associated with the primary outcome [adjHR = 1.33 (95% CI: 1.12-1.58), P = 0.001]. In an observational cohort resembling the main OCEAN(a)-Outcomes Trial enrolment criteria, patients with an Lp(a) ?200 nmol/L had a higher risk of cardiovascular outcomes.
  • ||||||||||  Journal:  Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. (Pubmed Central) -  Aug 29, 2023   
    Established pharmaceutical treatment options include the Niemann-Pick-C1 like-1 protein (NPC1L1) inhibitor ezetimibe, the protein convertase subtilisin-kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab, fibrates as peroxisome proliferator receptor alpha (PPAR-?) activators, and the omega-3 fatty acid icosapent ethyl...For secondary prevention in hypertriglyceridemia, second-line options such as statin add-on or statin-intolerant treatments are icosapent ethyl and fenofibrate...Recent biotechnological advances have led to the development of innovative small molecules (bempedoic acid, lomitapide, pemafibrate, docosapentaenoic and eicosapentaenoic acid), antibodies (evinacumab), antisense oligonucleotides (mipomersen, volanesorsen, pelcarsen, olezarsen), small interfering RNA (inclisiran, olpasiran), and gene therapies for patients with dyslipidemia...Apart from statins, data on new drugs' use in primary cardiovascular prevention remain scarce. For their swift adoption into clinical routine, these treatments must demonstrate safety and efficacy as well as cost-effectiveness in randomized cardiovascular outcome trials.
  • ||||||||||  erfonrilimab (KN046) / Alphamab, Stivarga (regorafenib) / Bayer
    Enrollment open, Combination therapy, IO biomarker, Metastases:  KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 29, 2023   
    P2,  N=98, Recruiting, 
    Both ZOL and Dmab are suggested to be effective sequential treatments after TPT. Not yet recruiting --> Recruiting
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Retrospective data, Review, Journal:  Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. (Pubmed Central) -  Aug 28, 2023   
    Medications used in the management of osteoporosis in women appear to provide similar benefits in men with osteoporosis. Therefore, the algorithm for the management of osteoporosis in men could be similar to the one previously recommended for the management of osteoporosis in women.
  • ||||||||||  Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
    Review, Journal:  Equivalence assessment of biotherapeutics with N- and O-glycosylation sites by sequential intact glycoform mass spectrometry (IGMS). (Pubmed Central) -  Aug 28, 2023   
    In addition, we performed a comparative assessment of the heterogeneity from different products, confirming that our new method can efficiently evaluate glycosylation equivalence. This new strategy provides rapid and accurate information on the degree of glycosylation of a therapeutic glycoprotein with multiple glycosylation, which can be used to assess glycosylation similarity between batches and between biosimilar and reference during development and production.
  • ||||||||||  Vectibix (panitumumab) / Amgen, Takeda
    Journal:  Exploring proteoforms of the IgG2 monoclonal antibody panitumumab using microchip capillary electrophoresis-mass spectrometry. (Pubmed Central) -  Aug 28, 2023   
    If not separated before mass spectrometric analysis, e.g. by capillary electrophoresis, such near isobaric species coalesce into single MS peaks, which subsequently hampers or prevents their assignment. With a total of 42 panitumumab isoforms assigned by CE-MS, these observations highlight a potential pitfall of commonly applied rapid identity testing workflows and demonstrate that even low complexity biopharmaceuticals can require separation strategies which offer high separation selectivity for species close in mass.
  • ||||||||||  Review:  Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review. (Pubmed Central) -  Aug 28, 2023   
    Data from head-to-head trials have shown greater efficacy of ixekizumab over adalimumab and ustekinumab, as well as brodalumab over ustekinumab, while prior meta-analyses have demonstrated superiority of ixekizumab and tofacitinib to other included agents at various assessed timepoints. Further studies on the long-term efficacy and safety of these agents, as well as randomized controlled trials involving comparison with placebo arms, are needed to fully analyze differences in efficacy of newer agents compared with previously established therapies.
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    Trial completion date, Trial primary completion date:  SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) -  Aug 28, 2023   
    P1,  N=403, Recruiting, 
    Trial primary completion date: Jul 2023 --> Jul 2024 Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Aug 2024